Cargando…

NEIM-01 INCIDENCE AND DIAGNOSTIC TECHNIQUES FOR LEPTOMENINGEAL DISEASE IN PATIENTS WITH BRAIN METASTASIS

BACKGROUND: Leptomeningeal disease (LMD) is malignant infiltration of the pia mater and cerebrospinal fluid (CSF) space. LMD carries a poor prognosis with median survival of a few months. Annually, 110,000 patients in the United States are diagnosed with LMD. The incidence is rising because of impro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Henry, Katie, Overholt, Brandon, Sinson, Grant, Pinheiro, Fernando Santos, Bovi, Joseph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354214/ http://dx.doi.org/10.1093/noajnl/vdac078.068

Ejemplares similares

NEIM-04 LEVERAGING NOVEL NEUROIMAGING TECHNIQUES TO LINK BRAIN METASTASES AND LOCAL GENE EXPRESSION
por: Germann, Jurgen, et al.
Publicado: (2022)

NEIM-13 THE PROGNOSTIC ROLE OF VENTRICULAR SIZE AND ITS DYNAMICS IN PATIENTS WITH LEPTOMENINGEAL METASTASIS FROM SOLID TUMORS
por: Le Rhun, Emilie, et al.
Publicado: (2023)

NEIM-02 DEVELOPMENT OF A DEEP LEARNING MODEL FOR DISCRIMINATING TRUE PROGRESSION FROM PSEUDOPROGRESSION IN GLIOBLASTOMA PATIENTS
por: Moassefi, Mana, et al.
Publicado: (2022)

SPCR-02 NEUROCOGNITIVE FUNCTION IN PATIENTS WITH LEPTOMENINGEAL METASTASIS TREATED WITH PROTON CRANIOSPINAL IRRADIATION
por: Correa, Denise, et al.
Publicado: (2022)

BSCI-08 NEURONAL MIMICRY PROMOTES BREAST CANCER LEPTOMENINGEAL METASTASIS FROM BONE MARROW
por: Whiteley, Andrew, et al.
Publicado: (2022)

NEIM-01 IMMUNOSUPPRESSION IN THE GLIOMA MICROENVIRONMENT: USING PET IMAGING TO HIGHLIGHT THE PRESENCE OF TIGIT
por: Frederico, Stephen, et al.
Publicado: (2023)

NEIM-03 A MULTICENTER PHASE 3 TRIAL IN PROGRESS: DIAGNOSTIC PERFORMANCE OF(18)F-FLUCICLOVINE PET FOR THE DETECTION OF RECURRENT BRAIN METASTASES AFTER RADIATION THERAPY (REVELATE)
por: Chao, Samuel, et al.
Publicado: (2022)

41. PROGNOSTIC VALIDATION OF THE EANO ESMO CLASSIFICATION OF LEPTOMENINGEAL METASTASIS
por: Le Rhun, Emilie, et al.
Publicado: (2020)

ETMM-03. CANCER CELLS DEPLOY LIPOCALIN- 2 TO COLLECT LIMITING IRON IN LEPTOMENINGEAL METASTASIS
por: Chi, Yudan, et al.
Publicado: (2021)

NEIM-08 A PHASE II STUDY OF MULTIPARAMETRIC MR-GUIDED HIGH DOSE ADAPTIVE RADIOTHERAPY WITH CONCURRENT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
por: Kim, Michelle, et al.
Publicado: (2022)

40. AN UPDATE ON THE DEVELOPMENT OF A NEW TOOL TO ASSESS RESPONSE IN LEPTOMENINGEAL METASTASIS
por: Weller, Michael, et al.
Publicado: (2020)

21. A PHASE II TRIAL OF COMPREHENSIVE TREATMENT BASED ON RADIOTHERAPY IN LEPTOMENINGEAL METASTASIS
por: Yang, Siran, et al.
Publicado: (2020)

NEIM-07 DIFFERENTIAL DIAGNOSIS OF TUMOR RECURRENCE AND RADIATION NECROSIS AFTER STEREOTACTIC RADIOTHERAPY FOR BRAIN METASTASES WITH 320-ROW ADCT PERFUSION IMAGE AND T1/T2 MATCH: RADIOLOGICAL AND PATHOLOGICAL ANALYSIS
por: Mitsuya, Koichi, et al.
Publicado: (2022)

OMRT-15. Multidisciplinary management of non-small cell lung cancer patients with leptomeningeal metastasis in the TKI era
por: Chen, Kuan-Yu, et al.
Publicado: (2021)

Advances in the diagnosis, evaluation, and management of leptomeningeal disease
por: Sener, Ugur, et al.
Publicado: (2021)

BSCI-01. Small RNAseq analysis of microRNAs in brain metastasis
por: Jancalek, Radim, et al.
Publicado: (2021)

NEIM-05 FEASIBILITY OF NAVIGATED TRANSCRANIAL MAGNETIC STIMULATION (NTMS) BASED DIFFUSION TENSOR IMAGING (DTI) TRACTOGRAPHY OF MOTOR PATHWAYS IN PATIENTS UNDERGOING STEREOTACTIC RADIOSURGERY: A CROSS-SECTIONAL DOSIMETRIC AND PATIENT OUTCOMES ANALYSIS
por: Bronk, Julianna, et al.
Publicado: (2022)

Leptomeningeal Metastasis: The Role of Cerebrospinal Fluid Diagnostics
por: Bönig, Lena, et al.
Publicado: (2019)

Leptomeningeal Metastasis: A Review of the Pathophysiology, Diagnostic Methodology, and Therapeutic Landscape
por: Nguyen, Andrew, et al.
Publicado: (2023)

BSCI-01 INTRATHECAL DELIVERY OF DENDRITIC CELL VACCINE ERADICATES TUMOR GROWTH AND PROTECTS AGAINST LEPTOMENINGEAL DISEASE (LMD) RE-INOCULATION IN IMMUNOCOMPETENT HER2+ AND TRIPLE NEGATIVE BREAST CANCER (TNBC) LMD XENOGRAFT MODELS
por: Law, Vincent, et al.
Publicado: (2022)

LPTO-01. LEPTOMENINGEAL METASTASIS FROM OVARIAN CARCINOMA TREATED WITH SYSTEMIC HIGH-DOSE METHOTREXATE
por: Coffee, Elizabeth, et al.
Publicado: (2019)

LMD-10. The role of immune checkpoint inhibitors in leptomeningeal disease: a systematic review
por: Palmisciano, Paolo, et al.
Publicado: (2021)

LMD-22. Clinicopathological spectrum of leptomeningeal metastases: A 3 year retrospective study
por: Pahwa, Saloni, et al.
Publicado: (2021)

LMD-21. Headache Improvement Predicts Survival after CSF diversion in Leptomeningeal Disease
por: Robin, Adam, et al.
Publicado: (2021)

OTME-17. Single cell characterization of the immune microenvironment of melanoma brain and leptomeningeal metastases
por: Smalley, Inna, et al.
Publicado: (2021)

56. TUMOR-HOMING STEM CELL THERAPY INHIBITS THE PROGRESSION OF BREAST CANCER LEPTOMENINGEAL CARCINOMATOSIS
por: Jiang, Wulin, et al.
Publicado: (2020)

11. ASSOCIATION OF TUMOR EXPOSURE TO CEREBROSPINAL FLUID SPACES TO LEPTOMENINGEAL DISEASE IN PATIENTS WITH BRAIN METASTASES
por: Patel, Kunal, et al.
Publicado: (2020)

LMD-02. Cerebrospinal Fluid Diversion for Metastatic Leptomeningeal Carcinomatosis: Palliative, Procedural and Oncologic Outcomes
por: Bander, Evan D, et al.
Publicado: (2021)

LMD-19. Anatomic and Surgical Factors Predict Development of Leptomeningeal Disease in Patients with Metastatic Melanoma
por: Lowe, Stephen, et al.
Publicado: (2021)

LMD-06. A NSCLC patient with leptomeningeal metastasis harboring rare EGFR mutations G719S and L861Q benefited from doubling dosage of osimertinib: a case report
por: Wang, Hui, et al.
Publicado: (2021)

MET-01 Linac-based fractionated stereotactic radiotherapy with micro-multileaf collimeter for large brain metastasis unsuitable for surgical resection
por: Matsuda, Ryosuke, et al.
Publicado: (2020)

LMD-18. Detection and serial monitoring of CSF ctDNA in breast cancer leptomeningeal disease (BCLM)
por: Fitzpatrick, Amanda, et al.
Publicado: (2021)

LMD-14. Preclinical safety and activity of intraventricular Rhenium-186 Nanoliposome ((186)RNL) for leptomeningeal metastases
por: Guerra-Garcia, Maria, et al.
Publicado: (2021)

LMD-09. Outcomes and symptom benefit from palliative radiotherapy for leptomeningeal disease in breast cancer patients
por: Takayesu, Jamie, et al.
Publicado: (2021)

Effect of Treatment Modality on the Hypothalamic–Pituitary Function of Patients Treated with Radiation Therapy for Pituitary Adenomas: Hypothalamic Dose and Endocrine Outcomes
por: Elson, Andrew, et al.
Publicado: (2014)

SPIN-01 RADIATION THERAPY ALONE VERSUS RADIATION THERAPY PLUS RADIOFREQUENCY ABLATION/VERTEBRAL AUGMENTATION FOR SPINE METASTASIS: TRIAL IN PROGRESS
por: Kotecha, Rupesh, et al.
Publicado: (2022)

Diagnostic Value of CYFRA 21-1 in the Cerebrospinal Fluid for Leptomeningeal Metastasis
por: Zhang, Zhen, et al.
Publicado: (2017)

LMD-04. FLAIR hyperintensity along the brainstem surface in leptomeningeal metastases: a case series and literature review
por: Mitsuya, Koichi, et al.
Publicado: (2021)

LMD-12. Ubiquitin Conjugating Enzymes promote leptomeningeal dissemination and decrease survival in patients with brain metastatic disease
por: Paisana, Eunice, et al.
Publicado: (2021)

23. RETROSPECTIVE REVIEW OF ADULT PATIENTS WITH LEPTOMENINGEAL DISEASE SECONDARY TO MELANOMA AT MOFFITT CANCER CENTER: DIAGNOSIS, TREATMENT AND OUTCOMES
por: Pina, Yolanda, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1t1m8jtmon2ifpe0kqg7bu568j